Efficacy and safety of lenvatinib plus gefitinib in lenvatinib-resistant hepatocellular carcinomas: a prospective, single-arm exploratory trial

Efficacy and safety of lenvatinib plus gefitinib in lenvatinib-resistant hepatocellular carcinomas: a prospective, single-arm exploratory trial

Abstract Lenvatinib, a multi-kinase inhibitor, has been approved as first-line treatment for advanced hepatocellular carcinoma (HCC), but its efficacy is limited. We have shown previously that lenvatinib and epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) combination therapy ov...

Full description

Saved in:
Bibliographic Details
Main Authors: Yaoping Shi, Dan Cui, Lei Xia, Donghua Shi, Guangxin Jin, Siying Wang, Yan Lin, Xiaoyin Tang, Jiachang Chi, Tao Wang, Meng Li, Zicheng Lv, Jiaojiao Zheng, Qi Jia, Wu Yang, Zhen Sun, Fan Yang, Hao Feng, Shengxian Yuan, Weiping Zhou, Wenxin Qin, Rene Bernards, Haojie Jin, Bo Zhai
Format: Article
Language:English
Published: Nature Publishing Group 2024-12-01
Series:Signal Transduction and Targeted Therapy
Online Access:https://doi.org/10.1038/s41392-024-02085-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41392-024-02085-8

Similar Items